Overview
Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer
Status:
Recruiting
Recruiting
Trial end date:
2023-07-18
2023-07-18
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Samsung Medical CenterTreatments:
Candesartan
Criteria
Inclusion Criteria:- Female aged ≥ 18 years
- Pathologically confirmed HER2-positive breast cancer
- Adjuvant treatment plan comprises at least 12 cycles of Trastuzumab
- Baseline echocardiogram should be performed before starting trastuzumab
- Cumulative anthracycline dose ≤ 300mg/m2
- Written informed consent to participate in the study
Exclusion Criteria:
- History of hypersensitivity or alllergic reaction to the study medication
- Metastatic breast cancer
- Treatment with angiotensin converting enzyme(ACE) inhibitor , Angiotensin receptor
blocker (ARB), beta-blocking agents, or diuretics
- Patients with NCI/CTCAE grade ≥ 2 congestive heart failure, myocardial infarction,
symptomatic left ventricular systolic dysfunction, heart's valve disease (≥ moderate),
arrhythmias (Grade ≥ 3) < 12 months before enrollment
- Pregnancy or breast feeding
- Baseline systolic pressure < 90mmHg
- Cumulative anthracycline dose > 300mg/m2
- Serious concurrent illness